序号 |
标题 |
次数 |
作者 |
发布时间 |
66736 |
三分枝脂质体配体,3RGD-Chol,提供荧光脂质体定制服务 |
101 |
axc |
2024-12-18 |
66737 |
cas:1343476-44-7,Val-Ala-PAB-OH , ADC试剂 |
72 |
kx |
2024-12-18 |
66738 |
cas:28320-73-2,Boc-Gly-Gly-Gly-OH,ADC定制 |
108 |
wyh |
2024-12-18 |
66739 |
双分枝脂质体配体,2RGD-Chol,脂质体纳米载体定制服务 |
91 |
axc |
2024-12-18 |
66740 |
MC-Val-Cit-PAB-Gly, ADC试剂 |
74 |
kx |
2024-12-18 |
66741 |
DBCO-PEG4-Val-Ala-PAB,由DBCO、PEG4、Val、Ala和PAB组成 |
78 |
WYQ |
2024-12-18 |
66742 |
DBCO-PEG4-Val-Ala-PAB-PNP |
67 |
WYQ |
2024-12-18 |
66743 |
1343407-91-9,Alloc-Val-Ala-PAB-OH,ADC定制 |
105 |
wyh |
2024-12-18 |
66744 |
cas:870487-09-5,Boc-Val-Cit-PAB |
78 |
kx |
2024-12-18 |
66745 |
cas:2353409-69-3,Mal-PEG8-Val-Cit-PAB-MMAE,ADC定制 |
129 |
wyh |
2024-12-18 |
66746 |
cas:159858-33-0,Val-Cit ,L-缬氨酰基-L-瓜氨酸 |
64 |
kx |
2024-12-18 |
66747 |
单分枝脂质体配体,1RGD-Chol,多功能载药脂质体定制服务 |
59 |
axc |
2024-12-18 |
66748 |
1350456-56-2,Fmoc-Val-Cit-PAB-MMAE,ADC定制 |
116 |
wyh |
2024-12-18 |
66749 |
H-Val-Ala-OH(缬氨酰-丙氨酸),CAS号:27493-61-4 |
70 |
WYQ |
2024-12-18 |
66750 |
cas:1869126-64-6,Azido-PEG4-Val-Cit-PAB-MMAE,ADC定制 |
63 |
wyh |
2024-12-18 |
66751 |
cas:890409-85-5 , Py-ds-dmBut-OSu |
93 |
kx |
2024-12-18 |
66752 |
Val-Ala-PAB-OH,一种用于合成抗体药物偶联物(ADCs)的化学化合物 |
91 |
WYQ |
2024-12-18 |
66753 |
重组E.coli细胞表达类弹性蛋白多肽-超氧化物歧化酶融合蛋白脂质体,ELP-SOD |
131 |
axc |
2024-12-18 |
66754 |
cas:1222490-34-7 , PBD-dimer PBD二聚体 |
70 |
kx |
2024-12-18 |
66755 |
Azido-PEG4-Val-Ala-PAB,分子式:C29H48N8O9 |
99 |
WYQ |
2024-12-18 |
66756 |
cas:1394238-91-5,Fmoc-Val-Ala-PAB,ADC定制 |
73 |
wyh |
2024-12-18 |
66757 |
多柔比星脂质体,多功能载药脂质体定制服务 |
102 |
axc |
2024-12-18 |
66758 |
cas:1869126-64-6 , Azido-PEG4-Val-Cit-PAB-MMAE,叠氮-四聚乙二醇-VAL-CIT-PAB-MMAE |
70 |
kx |
2024-12-18 |
66759 |
Ald-CH2-PEG5-t-butyl ester,cas:1446282-23-0 |
92 |
zyl |
2024-12-18 |
66760 |
DOTA-anti-CITED1-PNA DOTA-anti-转化激活因子-肽核酸 |
62 |
h |
2024-12-18 |
66761 |
Mal-Val-Ala-PAB,一种可降解的ADC连接子 |
110 |
|
2024-12-18 |
66762 |
cas:2504147-59-3 , MC(C5)-Val-Cit, ADC试剂 |
81 |
kx |
2024-12-18 |
66763 |
UCHSM-DOTA 上转换发光纳米颗粒偶联DOTA双功能螯合剂 |
72 |
h |
2024-12-18 |
66764 |
cas:2055024-60-5,NH2-PEG6-Val-Cit-PAB-OH,ADC定制 |
58 |
wyh |
2024-12-18 |
66765 |
高负载姜黄脂质体粉,载药脂质体定制服务 |
85 |
axc |
2024-12-18 |
66766 |
Mal-PEG4-Val-Ala-PAB,一种可降解的ADC连接子 |
120 |
WYQ |
2024-12-18 |
66767 |
mal-DOTA 马来酰亚胺偶联DOTA大环配体 |
80 |
h |
2024-12-18 |
66768 |
cas:2055024-58-1,Fmoc-PEG4-Val-Cit-PAB-OH,ADC定制 |
72 |
wyh |
2024-12-18 |
66769 |
NOTA-HER2-Nb复合物 NOTA偶联HER2纳米抗体探针 |
57 |
h |
2024-12-18 |
66770 |
Mal-Val-Ala-PAB-PNP,具有良好的水溶性和化学稳定性 |
77 |
WYQ |
2024-12-18 |
66771 |
cas:2647914-16-5 , Fmoc-Gly3-Val-Cit-PAB-PNP |
62 |
kx |
2024-12-18 |
66772 |
DOTA-nimotuzumab 螯合剂DOTA偶联尼妥株单抗 |
55 |
h |
2024-12-18 |
66773 |
t-Boc-N-amido-PEG12-CH2COOH烷基链试剂 |
71 |
zyl |
2024-12-18 |
66774 |
羧甲基壳聚糖水溶液修饰越橘叶黄酮脂质体,CMCS-L6-Lips,靶向脂质体定制服务 |
92 |
axc |
2024-12-18 |
66775 |
1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸-D-苯丙氨酸1-酪氨酸3-苏氨酸8-OC DOTA-TATE |
62 |
h |
2024-12-18 |
66776 |
cas:1116085-99-4 , Phe-Lys(Trt)-PAB,L-苯丙氨酰-N-[4-(羟甲基)苯基]-N6-(三苯基甲基)-L-赖氨酰胺 |
77 |
kx |
2024-12-18 |
66777 |
DOTA-UMFNPs-FAPI-04 羟基琥珀酰亚胺-四氮杂环十二烷四乙酸修饰超顺磁锰铁氧纳米粒子 |
95 |
h |
2024-12-18 |
66778 |
Cu-DOTA@DA/HD Cu-DOTA共价接枝多巴胺-己二胺 |
114 |
h |
2024-12-18 |
66779 |
m-PEG4-(CH2)3-acid,cas:874208-84-1,三甘醇单甲醚丁酸 |
72 |
zyl |
2024-12-18 |
66780 |
28320-73-2,BOC-GLY-GLY-GLY-OH,N-[N-[N-[叔丁氧羰基]甘氨酰]甘氨酰]甘氨酸 |
81 |
kx |
2024-12-18 |